Zoe Doyle
Registered Nurse and Clinical Research Manager at University Health Network
Data updated
Papers
Trials
Research Footprint
Zoe Doyle appears in 9 tracked papers (2021–2026), most studied alongside Psilocybin and Ketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Anxiety Disorders.
Most-cited paper: Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin (89 citations).
Frequent co-authors: Roger McIntyre, Jonathan Rosenblat and Shokouh Meshkat.
Background & Research
Zoe Doyle appears as an author on several recent psychiatric and psychedelic medicine papers, including psilocybin-assisted psychotherapy studies for treatment-resistant depression and bipolar II disorder. She is listed as a contact at Toronto Western Hospital (University Health Network) and is identified in trial records as a registered nurse/clinical research manager involved in ongoing UHN psilocybin studies.
Key Impact
She is a recurring clinical research author on multiple psilocybin-assisted psychotherapy and ketamine/depression studies, indicating involvement in a notable Canadian psychedelic psychiatry research program.
Collaboration Network
15 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Zoe Doyle's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Zoe Doyle is associated with.
University of Toronto
University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.
View stakeholder →University Health Network, Toronto
Toronto's largest research hospital network and home to the Nikean Psychedelic Psychotherapy Research Centre — Canada's first dedicated psychedelic research centre, funded by a $5 million donation. Led by Dr. Emma Hapke, UHN's centre conducts psilocybin-assisted therapy trials for cancer patients and body dysmorphic disorder, alongside MDMA research for PTSD.
View stakeholder →